Investors in the clinical-stage biotechnology company Kezar Life Sciences (NASDAQ: KZR) saw a 46% rise in stock this morning after the company announced interim results regarding a Phase 2 trial of KZR-616 – a new treatment for patients with proliferative lupus nephritis (LN).
Part of the companies MISSION clinical trials in order to test the responder rate of KZR-616 – The 24 week period proved critical in evaluating the success of the new treatment; in which patients received 60mg of KZR-616 once weekly in addition to existing background treatment.
The study was constructed with two points of efficacy, the first being the proportion of patients achieving a renal response measured by a 50% or greater reduction in urine protein to creatinine ratio at the end of the treatment. The second was the number of patients with a total renal response or partial renal response. The results showed 3 out of 5 patients were recorded with a 50% or more reduction in UPCR at week 25, with 4 out of 5 patients demonstrating a reasonable reduction in proteinuria to less than 0.8UPCR.
KZR stock was trading sideways until a spike in August reassured investors that the company still had a lot of growth potential. Following positive Q3 results just last week, it didn’t take much for investors to jump back on board – leaving the market heavily occupied by bulls thirsty for a slice of cutting-edge success.
Should You Invest in Kezar Life Sciences Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now